Smart Money
01- Insider Buying
- Activists
- Institutions
The Intelligence Layer For Public Markets
Monitor insider buying, activist campaigns, institutional accumulation and corporate catalysts through a single intelligence platform.
The Problem
Every day, thousands of filings, disclosures, announcements and transactions enter the market. Most investors never see them. Most platforms overwhelm users with data.
Information is abundant.
Intelligence is scarce.
Framework
Four lenses applied to every signal. Conviction emerges where they converge.
Example Signal
Not a price target. A scored, reasoned briefing — the way an analyst would frame it for an investment committee.
Brief · SEN-0427 · Compiled from public filings · 11 Jun 2026
| Date | Insider | Role | Shares | Price | Value |
|---|---|---|---|---|---|
| 02 Jun | Carlos M. Hernandez | Director | 16,000 | $61.84 | $0.99M |
| 08 Jun | Mark W. Sopp | EVP, CFO | 38,500 | $62.71 | $2.41M |
| 11 Jun | Lester L. Lyles | Director, Chair | 24,000 | $63.42 | $1.52M |
| Aggregate · open-market (code P) | 78,500 | $62.71 | $4.93M | ||
Weighted composite 87 / 100 · liquidity-adjusted — large-cap NYSE listing, ample volume, no execution haircut applied.
Three directors purchased in size within ten trading days, immediately following a margin-accretive government services award. Cluster buying of this density and timing has historically preceded re-rating in the name — the insiders are signalling conviction the market has not yet priced.
Philosophy
When insiders buy.
When activists emerge.
When institutions accumulate.
When corporate catalysts begin to matter.
When the odds shift.
Sentra is designed to identify those moments — the few that genuinely change the odds.
Intelligence Report
What members receive — a complete, balanced memo. The bull case and the bear case, stated with equal rigour.
Memo · SEN-0613 · Compiled from public filings · 12 Jun 2026
An activist has disclosed a position and is pressing for portfolio rationalisation. Concurrent institutional accumulation over two quarters suggests the campaign is gaining alignment. The setup pairs a credible catalyst path with a depressed valuation relative to life-science tools peers.
| Holder | Shares | Q / Q | Position |
|---|---|---|---|
| Index & ETF complex | 96.4M | +2.1M | Added |
| Global value manager | 38.7M | +6.9M | Added |
| Multi-strategy platform | 19.2M | +19.2M | New |
| Diversified pension | 11.5M | −0.8M | Trimmed |
Net institutional buying across both cycles, breadth skewed to accumulation (412 increasing against 287 decreasing). Next 13F window — 14 Aug 2026.
| EV / EBITDA (fwd) | 13.0× | Peer median 17.5× |
|---|---|---|
| Forward P / E | 16.5× | — |
| FCF Yield | 6.0% | Trailing twelve months |
| Net Debt / EBITDA | 3.5× | ~$4.2B net debt |
| Interest Coverage | 3.9× | Rate-sensitive |
| Discount To Peers | ~26% | On forward EV / EBITDA |
Held short of the 80s by a missing insider-buying corroborator and ~3.5× leverage that limits margin for error before the review lands.
Sources SEC Schedule 13D · Form 13F-HR · Form 10-Q · company disclosures. Point-in-time as of public dissemination.
Illustrative example compiled from public filings. For information only — not investment advice, not a recommendation, and not a price target. Capital at risk.
Membership
Everything Sentra sees.
Everything Sentra scores.
Everything Sentra publishes.
No tiers. No enterprise upsell. No free plan diluting the work. One price, for the full intelligence stream.
Everything Sentra sees. Everything Sentra scores. Everything Sentra publishes.
Cancel anytime. No contracts. Founding members keep their pricing as Sentra grows.